Navigating Systemic Therapy Options in HER2+ Breast Cancer
Panelists discuss a high-level overview of systemic therapies for advanced HER2+ breast cancer, outlining the roles of HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs) in treatment, as well as treatment strategies for patients with brain metastases. They also explore the shared decision-making process that informed the recommendation of the HER2CLIMB regimen.
EP: 1.Overview of HER2 Breast Cancer
EP: 2.HER2+ Breast Cancer Diagnosis: Insights From Patients and Clinicians
EP: 3.Coordinating Care for HER+ Breast Cancer Patients: A Multidisciplinary Approach
EP: 4.Multidisciplinary Care of HER2+ Breast Cancer: A Patient Perspective
EP: 5.Tailoring Patient Education and Resources in HER2+ Breast Cancer
EP: 6.Navigating HER2+ Breast Cancer Treatment: A Patient's Journey
Now Viewing
EP: 7.Navigating Systemic Therapy Options in HER2+ Breast Cancer
EP: 8.Key Insights from the HER2CLIMB Trial
EP: 9.Key Insights From the DEBBRAH and HER2CLIMB-02 Studies
EP: 10.BRIDGET Trial: Strategies in Maintenance Therapy for HER2+ Breast Cancer with Brain Metastases
EP: 11.Preparing Patients for Treatment: Education, Administration and Adverse Effect Management in HER2+ Breast Cancer
EP: 12.Patient Perspectives on Managing Adverse Effects from Capecitabine, Trastuzumab, and Tucatinib
EP: 13.Comprehensive Supportive Care for Metastatic HER2+ Breast Cancer
EP: 14.Patient Perspective: Key Aspects of Supportive Care in the HER2+ Breast Cancer Journey
EP: 15.Future Perspectives in HER2+ Breast Cancer
EP: 16.Closing Thoughts: Key Messages for Clinicians and Patients in the Treatment of HER2+ Breast Cancer
EP: 17.Discussing, Managing, and Treating HER2+ Breast Cancer From the Patient’s Perspective
- Dr Iyengar: Please provide a high-level overview of the systemic therapies that you consider for advanced HER2+ breast cancer. (sSee NCCN Guidelines Version 2.2024.)
- What is the role of HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and ADCs in treating advanced HER2+ breast cancer?
- How do you typically manage treat patients with advanced HER2+ breast cancer and brain metastases?
- Following Dorian’s evaluation, how did the shared decision-making process unfold, and what factors ultimately led you to recommend the HER2CLIMB regimen (trastuzumab [Herceptin] and + tucatinib [Tukysa] and capecitabine [Xeloda])?
Recent Videos
Related Content
